2021 American Transplant Congress
Changes in Cytomegalovirus Specific T Cell Immunity With Immunomodulation in Serodiscordant High Risk Transplant Recipients
Virginia Commonwealth University Health, Richmond, VA
*Purpose: Cytomegalovirus (CMV) infections cause significant morbidity and mortality among all solid organ transplant recipients. CMV discordant (D+/R-) recipients are at higher risk of developing…2021 American Transplant Congress
Letermovir Prophylaxis in Solid Organ Transplant – CMV Breakthrough and Tacrolimus Drug Interaction
*Purpose: Valganciclovir is the preferred drug for cytomegalovirus (CMV) prophylaxis in solid organ transplantation. A limitation to its use is profound myelosuppression. Letermovir is a…2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…2021 American Transplant Congress
Ganciclovir Therapeutic Drug Monitoring in Obese Adults Patients – Opportunity for Clinical Utility
*Purpose: Ganciclovir (GCV) is the drug of choice for the treatment of cytomegalovirus (CMV) infection; optimal dosing of GCV in the obese patient population is…2021 American Transplant Congress
Cytomegalovirus (CMV) D+/R- Serostatus is Independently Associated with Mortality and Graft Loss After Liver Transplantation (LTx)
Internal Medicine, University of Washington Medical Center, Seattle, WA
*Purpose: It is unknown if donor or recipient (D/R) CMV serostatus, in the era of CMV prophylactic and pre-emptive strategies, remains associated with clinical outcomes…2021 American Transplant Congress
Outcomes Among CMV Mismatched and Highly Sensitized Kidney Transplant Recipients Who Develop Leukopenia or Neutropenia
*Purpose: Kidney transplant recipients (KTRs) who receive antiproliferative agents for immunosuppression and valganciclovir for CMV prophylaxis are at high risk of developing leukopenia and neutropenia.…2021 American Transplant Congress
Cmv Specific Cellmediated Immune Reconstitution During Letermovir Prophylaxis in High Risk Hematopoietic Cell Transplant Recipients
*Purpose: Patients who are cytomegalovirus (CMV) seropositive (R+) prior to hematopoietic cell transplant (HCT), have a 30% incidence of clinically significant CMV reactivation in the…2021 American Transplant Congress
Evaluation of Low Dose Famciclovir as Herpes Simplex Virus and Varicella Zoster Virus Prophylaxis in Cytomegalovirus Low Risk Solid Organ Transplant Recipients
Massachusetts General Hospital, Boston, MA
*Purpose: Famciclovir is recommended for herpes simplex virus (HSV) and varicella-zoster virus (VZV) prophylaxis in cytomegalovirus (CMV) low risk (both donor and recipient CMV seronegative)…2021 American Transplant Congress
Impact of a Cmv Cell Mediated Immunity Based Protocol on Guiding Cmv Prophylaxis Following Pediatric Liver Transplantation – A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is an important cause of morbidity following pediatric orthotopic liver transplantation (OLT), especially among high risk (HR) CMV D+/R- recipients. In 2019,…2021 American Transplant Congress
Survival Outcomes in Kidney Transplant Recipients Aged 18-60 Years by CMV Discordance Status: A Multivariable Analysis
*Purpose: Despite advances in CMV therapeutics, CMV infection can pose significant comorbidity after transplantation. We sought to examine the impact of high-risk CMV discordance in…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 33
- Next Page »